MOTUS Total Joint Replacement Investigational Device Exemption Study
An Interventional, Multi-center Investigation of the MOTUS Total Joint Replacement
1 other identifier
interventional
158
1 country
14
Brief Summary
This study is designed to collect safety and efficacy data on patients who plan to undergo a single-level total joint replacement of the lumbar spine using the MOTUS device (MOTUS Total Joint Replacement procedure) to demonstrate noninferiority to lumbar interbody fusion with respect to composite endpoints.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2022
Longer than P75 for not_applicable
14 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 22, 2022
CompletedStudy Start
First participant enrolled
June 23, 2022
CompletedFirst Posted
Study publicly available on registry
June 30, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 9, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
June 13, 2029
ExpectedJune 29, 2026
June 1, 2026
3.6 years
June 22, 2022
June 26, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Oswestry Disability Index (ODI) Score
Improvement of at least 15 points in ODI score (out of 100). The ODI is a self-reported questionnaire that contains ten sections concerning intensity of pain, lifting, personal care, walking, sitting, sexual function, standing, social life, sleeping and traveling.
24 months compared to baseline
Neurological Status
Absence of deterioration in neurological status compared to baseline examinations. Neurological examination will consist of a motor and sensory examination at each in person study visit conducted per physician standard of care. These data will be adjudicated by the Clinical Events Committee (CEC).
24 months compared to baseline
Subsequent Surgical Intervention (SSI)
Subject success will be determined with the absence of a subsequent surgical intervention including revision, re-operation, removal, or supplemental fixation at the index level.
24 month
Serious device-related adverse events (SDAE)
Subject success will be determined with the absence of any serious device-related adverse events (SDAE). These data will be adjudicated by the Clinical Events Committee (CEC).
24 month
Secondary Outcomes (7)
Visual Analog Score (VAS) - Worst Leg
24 months
VAS - Back
24 months
ODI
24 months
ODI
24 months
VAS
24 months
- +2 more secondary outcomes
Other Outcomes (3)
Patient-Reported Outcomes Measurement Information System (PROMIS)
24 months
Demographics and Intra-operative variables
24 months
Time to first SSI
24 months
Study Arms (1)
MOTUS
EXPERIMENTALAll subjects will be treated with the MOTUS Total Joint Replacement
Interventions
The MOTUS Total Joint Replacement is indicated for the biomechanical reconstruction and stabilization of a spinal motion segment following decompression at one lumbar level from L1/L2 to L5/S1 for skeletally mature patients due to symptomatic lumbar degeneration with or without foraminal or recess spinal stenosis confirmed by radiographic imaging (CT, MRI, X-rays), with no more than a Grade 1 spondylolisthesis at the involved level.
Eligibility Criteria
You may qualify if:
- Male or female, age 21-80 (inclusive) with at least 3 years of life expectancy;
- The subject has a primary diagnosis of symptomatic lumbar degeneration with or without foraminal or recess stenosis of the lumbar spine at a single level from L1/L2 to L5/S1 confirmed by subject history and radiographic imaging (CT, MRI, X-rays) with no more than a Grade 1 (\<25% translation) spondylolisthesis. Symptomatic lumbar degeneration that may be associated with a co-morbid condition such as:
- Herniated nucleus pulposus;
- Scarring/thickening of the ligamentum flavum, annulus fibrosus, or facet joint capsule;
- Facet joint degeneration/osteophyte formation;
- Spondylosis (defined by the presence of osteophytes);
- Disc degeneration and/or annular degeneration; and/or
- Lumbar stenosis defined by spinal cord or nerve root compression;
- Exhausted conservative treatment (e.g. bed rest, physical therapy, medications, TENS, manipulation, and/or spinal injections) for at least 3 months or has a neurologic emergency;
- Preoperative Oswestry Disability Index score ≥ 40/100 at baseline;
- Psychosocially, mentally, and physically able and willing to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms; and
- Signed informed consent.
You may not qualify if:
- More than one vertebral level requiring treatment with instrumentation;
- Previous instrumented surgery (i.e.: anterior disc replacement, spinal fusion, interspinous device, etc.) at the index lumbar level or an adjacent level;
- Degenerative or lytic spondylolisthesis greater than Grade 1 (25% translation) associated with congenital (e.g. dysplastic) pars defects;
- Rotatory scoliosis (\>10 degrees) at the index level;
- Congenital bony and/or spinal cord abnormalities at the level to be treated such as conjoined nerve roots that would otherwise prevent placement of the device without generating nerve damage or skeletal malformations such as kyphotic vertebra that may be better suited for a different course of treatment (e.g. spinal fusion);
- Subcaudal defect, disrupting the integrity of the pedicle that presents undue risk of device subsidence or migration due to compromised bone quality/density;
- Clinically compromised vertebral bodies at the index level due to current or past trauma, e.g., by the radiographic appearance of the fracture callus, malunion or nonunion;
- Disrupted anterior longitudinal ligament at the index level;
- Overlying thoracolumbar kyphosis (greater than or equal to 15 degrees) within one level (includes target and adjacent level) of the level to be treated;
- Back pain of unknown etiology without leg pain;
- Severe spondylosis at the level to be treated as characterized by any of the following:
- Autofusion (solid arthrodesis) determined radiographically (CT);
- Totally collapsed disc, or;
- Vertebral body that cannot be mobilized;
- Known allergy to cobalt, chromium, molybdenum, nickel, polyethylene, titanium, or vitamin E;
- +27 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- 3Spinelead
Study Sites (14)
Todd H. Lanman, MD Inc.
Los Angeles, California, 90210, United States
Steamboat Orthopaedic & Spine Institute (SOSI)
Steamboat Springs, Colorado, 80487, United States
Spine and Orthopedic Center
Deerfield Beach, Florida, 33441, United States
Florida Orthopaedic Institute
Temple Terrace, Florida, 33637, United States
Strenge Spine Centert
Paducah, Kentucky, 42003, United States
Spine Institute of Louisiana
Shreveport, Louisiana, 71101, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
Upstate Orthopedics
East Syracuse, New York, 13057, United States
NYU Langone
New York, New York, 10016, United States
Pinehurst Surgical Clinic
Pinehurst, North Carolina, 28374, United States
Oklahoma Spine Center
Oklahoma City, Oklahoma, 73170, United States
Center for Sports Medicine and Orthopaedics
Chattanooga, Tennessee, 37404, United States
Ortho San Antonio
San Antonio, Texas, 78229, United States
The Disc Replacement Center
West Jordan, Utah, 84088, United States
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 22, 2022
First Posted
June 30, 2022
Study Start
June 23, 2022
Primary Completion
February 9, 2026
Study Completion (Estimated)
June 13, 2029
Last Updated
June 29, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share
This trial uses data for a motion-preserving spine implant for a US FDA regulated PMA application. These data are proprietary and thus access is managed accordingly with dissemination considered after completion of FDA review. Beyond providing clinical evidence for a PMA, we plan to share findings through peer-reviewed publications \& scientific presentations. Prior to public release, data is reviewed for consistency with protocol, informed consent, participant confidentiality \& regulatory requirements. Data is verified for accuracy \& completeness, including demographics, operative details, functional assessments \& PROMs. After FDA review, de-identified data will be available to qualified investigators upon request contingent upon sponsor approval, available budget, a signed data use agreement, compliance with HIPAA \& terms of patient informed consent. The sponsor shall review requests for scientific merit, requestor qualifications, patient consent alignment \& regulatory obligations.